Differentiation of Meningiomas and Gliomas by Amide Proton Transfer Imaging: A Preliminary Study of Brain Tumour Infiltration

Han-Wen Zhang1, Xiao-Lei Liu1, Hong-Bo Zhang2, Ying-Qi Li3, Yu-li Wang1, Yu-Ning Feng1, Kan Deng4, Yi Lei1*, Biao Huang5* and Fan Lin1*

1 Department of Radiology, The First Affiliated Hospital of Shenzhen University, Health Science Center, Shenzhen Second People’s Hospital, Shenzhen, China, 2 Department of Radiology, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, China, 3 Department of Radiology, Songgiang People’s Hospital, Shenzhen, China, 4 Research Department, Philips Healthcare, Guangzhou, China, 5 Department of Radiology, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Guangdong, China

Background: Gliomas are more malignant and invasive than meningiomas.

Objective: To distinguish meningiomas from low-grade/high-grade gliomas (LGGs/HGGs) using amide proton transfer imaging (APT) combined with conventional magnetic resonance imaging (MRI) and to explore the application of APT in evaluating brain tumour invasiveness.

Materials and Methods: The imaging data of 50 brain tumors confirmed by pathology in patients who underwent APT scanning in our centre were retrospectively analysed. Of these tumors, 25 were meningiomas, 10 were LGGs, and 15 were HGGs. The extent of the tumour-induced range was measured on APT images, T2-weighted imaging (T2WI), and MRI enhancement; additionally, the degree of enhancement was graded. Ratios (RAPT/T2 and RAPT/E) were obtained by dividing the range of changes observed by APT by the range of changes observed via T2WI and MR enhancement, respectively, and APTmean values were measured. The Mann-Whitney U test was used to compare the above measured values with the pathological results obtained for gliomas and meningiomas, the Kruskal-Wallis test was used to compare LGGs, HGGs and meningiomas, and Dunn’s test was used for pairwise comparisons. In addition, receiver operating characteristic (ROC) curves were drawn.

Results: The Mann-Whitney U test showed that APTmean (p=0.005), RAPT/T2 (p<0.001), and RAPT/E (p<0.001) values were statistically significant in the identification of meningioma and glioma. The Kruskal-Wallis test showed that the parameters APTmean, RAPT/T2, RAPT/E and the degree of enhancement are statistically significant. Dunn’s test revealed that RAPT/T2 (p=0.004) and RAPT/E (p=0.008) could be used for the identification of LGGs and meningiomas. APTmean (p<0.001), RAPT/T2 (p<0.001), and RAPT/E (p<0.001) could be used for the identification of HGGs and meningiomas. APTmean (p<0.001) was statistically
significant in the comparison of LGGs and HGGs. ROC curves showed that $R_{\text{APT/T2}}$ (area under the curve (AUC)=0.947) and $R_{\text{APT/E}}$ (AUC=0.919) could be used to distinguish gliomas from meningiomas.

**Conclusion:** APT can be used for the differential diagnosis of meningioma and glioma, but APT$_{\text{mean}}$ values can only be used for the differential diagnosis of HGGs and meningiomas or HGGs and LGGs. Gliomas exhibit more obvious changes than meningiomas in APT images of brain tissue; this outcome may be caused by brain infiltration.

**Keywords:** amide proton transfer, differential diagnosis, glioma, meningioma, MRI, tumour invasion

---

**ADVANCES IN KNOWLEDGE**

1. APT combined with conventional MR can be very good for the differential diagnosis of gliomas and meningiomas. APT can be used to differentiate among LGGs, HGGs and meningiomas.

2. Glioma APT images are larger than conventional MR images; therefore, gliomas are more obvious on these images than relatively benign meningiomas. This may be related to the infiltration of brain tumors.

---

**1 INTRODUCTION**

The Warburg effect, the theory that tumors metabolize acidic substances, is increasingly recognized by an increasing number of scientists studying tumors (1). In cutting-edge research, scientific experiments involving the abnormal accumulation of a series of acidic metabolites, such as methylglutaric acid, have repeatedly verified this viewpoint (2, 3). In the field of gliomas, Varun Venkataramani et al. proposed that glutamatergic synaptic input of glioma cells drives brain tumour progression, especially glioma progression (4). Compared with meningiomas with a significantly better survival prognosis, gliomas undoubtedly have a stronger ability to infiltrate the brain.

Due to the high recurrence rate and poor prognosis, gliomas have become a research hotspot in medicine (5). The main reason for the high recurrence rate of gliomas is the inability to effectively measure the boundary of the tumour infiltrated so that the gliomas cannot be radically removed (6). Neither long-term temozolomide chemotherapy nor radiotherapy in the later stage can effectively cure patients (7, 8). However, most meningiomas originating from the meninges, except for a very small number of malignant meningiomas, can be cured by excision. Meningiomas are directly supplied by meningeal blood vessels and show significant enhancement on enhanced magnetic resonance (MR) scans, and high-grade glioma (HGG)-induced blood–brain barrier (BBB) disruption can achieve a similar degree of enhancement (9).

According to the Warburg effect, malignant tumors cause acidic substances to accumulate in the infiltrating area. At present, clinical imaging technologies that can measure acidic metabolites include MR spectroscopy (MRS) and amide proton transfer imaging (APT) based on chemical exchange saturation transfer (CEST) (10, 11). APT technology can measure the amide proton content and indirectly reflect the protein content and pH value of a substance (12). At present, research on APT in gliomas mainly focuses on the use of the APT value for the evaluation of preoperative tumour malignancy and the identification of postoperative recurrence and pseudo-progression (13–15). However, there are only two studies on meningiomas, one on the content of Ki-67 in meningiomas and the other on the differential diagnosis of typical and atypical meningiomas (16, 17). At present, there is no research on the differential diagnosis of gliomas and meningiomas using APT technology.

In this study, APT was used to evaluate gliomas and meningiomas to obtain APT values, and the range of APT changes caused by tumors was measured and compared with the range of changes observed by conventional imaging of tumors. These analyses were performed to explore whether the changes in APT values and ranges caused by meningiomas and gliomas can be used for differential diagnosis.

---

**2 MATERIALS AND METHODS**

**2.1 Patients**

From January 2021 to February 2022, one hundred brain tumour patients who underwent Philips Ingenia 3.0 Tesla (T) MR imaging (MRI) scans were collected in our centre. Inclusion criteria were as follows (1): complete clinical data, no history of trauma and radiotherapy and chemotherapy (2); complete routine imaging before surgery, including T1-weighted imaging (T1WI), T2-weighted imaging (T2WI), enhanced scan, diffusion-weighted imaging (DWI) and APT, with satisfactory image quality diagnosis requirements; and (3) patients with postoperative pathological diagnosis of meningioma or glioma after surgical treatment.

Finally, 50 patients (25 males and 25 females) were included, including 25 patients with meningioma (12 males and 13 females) and 25 patients with gliomas (13 males and 12 females), aged 16-71 (48 ± 13) years old. This retrospective study was approved by the regional ethics committee and exempted from informed consent.

**2.2 MRI**

We scanned patients with a Philips Healthcare 3.0T Ingenia MR scanner (Philips Healthcare, Amsterdam, The Netherlands) using a
20-channel head coil. Patients fasted for 4-6 h before scanning. The localization line was located at the inferior border of the corpus callosum, and the scanning range was the whole brain. T1WI, T2WI, T2W-fluid attenuated inversion recovery (FLAIR), DWI, and APT scans were performed first, and then enhanced scans were performed.

2.2.1 Conventional MR Sequence
1. Axial T1WI parameters were as follows: repetition time (TR)/echo time (TE) = 2034/20 milliseconds (ms), section thickness = 5 mm, field of view (FOV) = 230 × 210 mm, and matrix = 328 × 258. 2. Axial T2WI parameters were as follows: TR/TE = 3000/105 ms, section thickness = 5 mm, FOV = 230 × 210 mm, and matrix = 328 × 258. 3. Coronal T2W-FLAIR parameters were as follows: TR/TE = 9000/81 ms, section thickness = 5 mm, inversion time = 2500 ms, FOV = 230 × 210 mm, and matrix = 328 × 258. 4. Axial DWI parameters were as follows: the B value of DWI is B = 0 and B = 1000 s/mm2, TR/TE = 3741/80 ms, section thickness = 5 mm, FOV = 230 × 210 mm, FOV = phase 100%, and matrix = 128 × 97.

2.2.2 APT and T1W-Enhanced Sequence
1. APT images were acquired axially (TR/TE=6306/8.3 ms, section thickness=5 mm, FOV=230×180 mm, and matrix=128×100). 2. An intravenous injection of gadodiamide (Omniscan, GE Healthcare, Dublin, Ireland) was carried out at an injection rate of 3.5 mL/s via a power injector (0.1 mmol/kg), followed by flushing with 10 mL of normal saline. Sagittal T1WI-enhanced parameters were as follows (TR/TE=6.8/3.1 ms, section thickness=1 mm, FOV=240×240 mm, and matrix=240×240).

2.3 Pathological Results
The pathological data of all patients included intraoperative pathology and immunohistochemical results. The pathological results of all glioma patients with complete molecular sequencing included isocitrate dehydrogenase, O6-methylguanine-DNA methyltransferase, telomere reverse transcriptase, etc.

The final pathological findings of the patients were obtained according to the 2016 edition of the CNS Tumour Classification.

2.4 Image Analysis
Conventional MR images were used for tumour extent measurements using ITK-SNAP-3.8.0 (University of Pennsylvania, Philadelphia, PA). The localization of the solid area of the tumour was performed on the T1WI structural image by three senior physicians, and the T2WI and enhanced scans were delineated. T2WI scans were marked, and the enhancement range was denoted as R\text{TE} and R\text{E}. A region of interest (ROI) was selected to avoid surrounding blood vessels, tumour necrosis and regions of cystic degeneration. At the same time, for the enhanced scan images, we scored the degree of enhancement on a 1–4 scale (1-no enhancement, 2-slight enhancement, 3-moderate enhancement, and 4-significant enhancement).

APT mean (APTmean) and range measurements (RAPT) were performed on APT images of tumors using IntelliSpace Portal 10.0 (Philips Medical, The Netherlands). T1WI structural images and the contralateral normal tissue areas served as references for the delineation of the range of APT image changes caused by tumors. Finally, we compared R\text{APT} with R\text{T2} and R\text{E} to obtain the corresponding ratios (R\text{APT/T2} and R\text{APT/E}) to determine whether the range of APT increased.

2.5 Statistical Analysis
We used the Statistical Package for the Social Sciences (SPSS v.19, Chicago, IL, USA) for data statistics. The intra/interclass correlation coefficients (ICCs) were used to calculate consistency between reviewers. Two-sided p values<0.05 were considered statistically significant. All data were calculated using the Shapiro-Wilk test, and the result was p<0.05, indicating that the data did not conform to a normal distribution. Because the data did not follow a normal distribution, the Mann–Whitney U test was used to evaluate differences in enhancement and APT images based on APTmean, R\text{APT/T2} and R\text{APT/E} between gliomas and meningiomas. The Kruskal-Wallis test was used to compare LGGs, HGGs and meningiomas, and Dunn’s test was used for pairwise comparisons. The area under the curve (AUC), confidence interval (CI) and cut-off values of the different types were calculated by receiver operating characteristic (ROC) curve analysis and the Youden Index. Following Bonferroni correction, p<0.01 indicated statistical significance. All statistical graphs were made using GraphPad Prism 7 (Prism 7, La Jolla, California).

3 RESULTS
3.1 Patients
The age and sex of the patients and the range of imaging (RT2, RE, and R\text{APT}) were not statistically significant. The interobserver agreement of all measurements between the three reviewers was excellent, with ICC values greater than 0.80. Basic patient information and imaging information are shown in Table 1.

3.2 Differentiation of Meningiomas and Gliomas by APT
Mann–Whitney U test results showed that the degree of enhancement (p=0.011), APTmean values (p=0.005), R\text{APT/E} values (p<0.001) and R\text{APT/T2} values (p<0.001) were statistically significant. This shows that R\text{APT/E} and R\text{APT/T2} can be used to distinguish gliomas and meningiomas to a better degree, and the change in APT range induced by gliomas is more obvious than that of meningiomas. Thus, the APTmean and enhancement degree can help differentiate gliomas from meningiomas.

The ROC curve analysis (Figure 1A) demonstrated that the R\text{APT/E} (AUC=0.947, CI: 0.886-1.000) and R\text{APT/T2} (AUC=0.919, CI: 0.886-1.000) values were significantly different between patients in the glioma and meningioma groups (p<0.001), which allowed a high diagnostic efficiency. The cut-off value for R\text{APT/E} was 1.116, with a sensitivity of 92% and a specificity of 92%. The cut-off value of R\text{APT/T2} was 1.092, with a sensitivity of 92% and a specificity of 88%. This shows that the changes in the APT range of most gliomas increased by more than 11.6% in contrast-enhanced images, and this change reached more than 9.2% when compared with that of T2WI images.
3.3 Differentiation of Meningiomas, LGGs and HGGs by APT

The Kruskal-Wallis test showed that the parameters APTmean, RAPT/T2, RAPT/E and the degree of enhancement were statistically significant (p<0.001).

3.3.1 Differentiation of Meningiomas From LGGs by APT

Dunn’s test results showed that the degree of enhancement (p<0.001), RAPT/E values (p=0.008) and RAPT/T2 values (p=0.004) were statistically significant, but not APTmean (p=0.01). Hence, the degree of enhancement, RAPT/E and RAPT/T2 can be used to distinguish LGGs from meningiomas. The enhancement degree of meningiomas is obviously stronger than that of LGGs, and the changes in APT images induced by LGGs are more obvious than those of meningiomas. However, since the APTmean of LGGs is close to that of meningiomas, this value cannot be used for differential diagnosis. Figure 2 shows a comparison of APT and conventional MR images of LGGs and meningiomas.

The ROC curve analysis (Figure 1B) demonstrated that the RAPT/E (AUC=0.908, CI: 0.809-1.000), RAPT/T2 (AUC=0.930, CI: 0.840-1.000), degree of enhancement (AUC=0.924, CI: 0.779-1.000) were significantly different between patients in the LGG and meningioma groups (p<0.01), which allowed high diagnostic efficiency. The cut-off value for RAPT/E was 1.104, with a sensitivity of 90% and a specificity of 86%. The cut-off value for RAPT/T2 was 1.095, with a sensitivity of 90% and a specificity of 92%. This shows that the changes in the APT range of most LGGs increased by more than 10.4% on contrast-enhanced images, and this change also reached more than 9.5% when compared with that of T2WI images. The enhanced image had a cut-off value of 1.5, a sensitivity of 100% and a specificity of 80%. This indicates that the enhancement of meningiomas is significantly stronger than that of LGGs.

3.3.2 Differentiation of Meningiomas From HGGs by APT

Dunn’s test results showed that the APTmean (p<0.001), RAPT/E (p<0.001) and RAPT/T2 (p<0.001) values were statistically significant. However, the degree of enhancement was not statistically significant (p>0.01). This shows that APTmean, RAPT/E and RAPT/T2 can be used to distinguish HGG and meningioma to a better degree. The APTmean of HGG is significantly higher than that of meningioma, and the changes in the APT image range brought by HGG are more obvious than those of meningioma. The enhancement degree of meningioma and HGG is mostly moderate or marked enhancement, so the degree of enhancement cannot be used to distinguish these two diseases.

In the ROC curve analysis (Figure 1C), RAPT/E (AUC=0.973, CI: 0.932-1.000), RAPT/T2 (AUC=0.912, CI: 0.782-1.000), APTmean (AUC=0.976, CI: 0.938-1.000) values were significantly different between patients in the HGG and meningioma groups (p<0.001), which allowed a high diagnostic efficiency. The cut-off value for RAPT/E was 1.123 with a sensitivity of 93.3% and a specificity of 88.0%. The cut-off value of RAPT/T2 was 1.101, the sensitivity was 86.7%, and the specificity was 92.0%. This shows that compared to that on enhanced images, the change in the APT range of HGGs increased by more than 12.3%, and this change also reached more than 10.1% compared with that on T2WI scans. The cut-off of the APT value was 3.840, the sensitivity was 93.3%, and the specificity was 92.0%. This finding indicated that the APTmean of HGGs was significantly higher than that of meningiomas.

3.3.3 Differential Diagnosis of LGGs and HGGs by APT

Dunn’s test results showed that the degree of enhancement (p=0.001) and APTmean (p<0.001) were statistically significant. However, RAPT/E (p=0.299) and RAPT/T2 (p=0.969) were not statistically significant (p>0.01). This shows that the APTmean and the enhancement degree can better distinguish HGGs and LGGs. HGGs usually have a high degree of enhancement, and the APTmean is also higher than that of LGGs.

The ROC curve analysis (Figure 1D) demonstrated that the enhancement (AUC=0.920, CI: 0.768-1.000) and APTmean (AUC=0.913, CI: 0.720-1.000) were significantly different between
patients in the HGG and LGG groups (p ≤ 0.001), which allowed a high diagnostic efficiency. The cut-off value of the APT value was 3.520, the sensitivity was 93.3%, and the specificity was 80.0%. The cut-off value for the degree of enhancement was 1.5, with a sensitivity of 100% and a specificity of 80%. This shows that the APT mean of HGGs is higher, and the enhancement degree is above moderate enhancement.

We briefly summarize the above statistical results in Table 2 for the differential diagnosis of HGG, LGG and meningioma. We sorted the invasiveness of glioma, LGG, and HGG compared with meningioma, as shown in Figure 3.

4 DISCUSSION

APT technology was first established by Zhou et al. of Johns Hopkins University by applying the most classic two-pool model, namely, a free water pool (solution) and an amide proton pool (solute) (18). Since peptides and proteins in the body generally contain amide bonds (-NH), the resonance frequency of hydrogen protons is 0 ppm, the resonance frequency of amide protons is 3.5 ppm, and the asymmetrical magnetization transfer rate (MTRasym) calculated by using the Z-spectrum can reflect the APT rate (19). Amide protons were saturated under continuous selective saturating radio frequency (RF) pulse irradiation. Exchange with free water via chemical shifts resulted in a reduction in the water signal. The reduction in this signal can indirectly reflect the changes in metabolites and pH changes in the substance; hence, it can be used to determine the content of amide protons in this region (20). This study used APT technology to study patients with gliomas and meningiomas and found an interesting phenomenon. The changes in the range of APT images caused by gliomas were more obvious than those of relatively benign meningiomas.
The use of conventional MRI for the diagnosis of glioma and meningioma is quite mature. For example, typical meningiomas have some obvious signs, such as the “meningeal tail” sign, which can be used for differential diagnosis. However, for the diagnosis of atypical meningioma or meningeal enhancement caused by glioma, APT technology can assist in the differential diagnosis to a certain extent. At the same time, combining APT with conventional MRI images has been shown to yield better diagnostic performance. For example, compared with significantly enhanced meningiomas, HGG has a higher \( APT_{\text{mean}} \) value, and the change range of APT images is larger than that of conventional images. APT measurements can help differentiate gliomas from meningiomas; however, these measurements are less effective for differentiating LGGs with a lower \( \text{MTR}_{\text{sym}} \) from meningiomas. However, the enlargement range of APT compared with traditional MR images caused by HGGs or LGGs is more obvious than that of meningiomas. We cannot directly conclude that this is the extent of glioma brain infiltration. Moreover, we have no pathological confirmation, but this change does exist compared to more benign meningiomas. Our study can only indicate that APT imaging may have some value in the determination of malignant brain tumour boundaries, but there is no doubt that this approach can be used in the differential diagnosis between gliomas and meningiomas.

In fact, the use of APT in the differential diagnosis of brain tumors is well established, but its use has mainly focused on the differentiation of solitary brain metastases (SBMs) and...
glioblastomas (GBMs) (21). Both Yu and Kamimura’s studies found that the APT value of GBMs was higher than that of SBMs, which can be used for the differential diagnosis of GBMs (22, 23). However, it is interesting that, in Kamimura’s study, we found that the APT value in the nonenhanced T2WI-increased area around GBMs was significantly higher than that in the corresponding T2WI-increased area of SBMs. Our study on gliomas and meningiomas also had similar results. Relatively benign meningiomas had lower APT values, but we found that gliomas caused changes in the APT range that were even larger than the range detected by T2WI, and LGGs also had similar performance to HGGs. The range of these changes was more than 9%, and these changes can even be directly judged by the naked eye. Combined with the enhancement degree and APT value, these changes can effectively help clinicians accurately identify gliomas and meningiomas.

“Ischaemic penumbra” is a concept of acute cerebral ischaemia, referring to the area of brain tissue that can be recovered with prompt medical treatment, usually referring to the area of brain tissue between DWI and perfusion-weighted imaging (PWI) (24). Gliomas also lead to the appearance of similar areas of tissue due to tumour brain infiltration, that is, the areas shown by conventional MR and the true borders of gliomas. The delineation of this boundary determines the extent of the operation and the prognosis of the patient’s survival (25). Similar to the use of intraoperative fluorescent probes, tumors can be radically removed as much as possible while preserving the patient’s normal brain tissue area (26). Our thinking is similar to that of most scholars; the changes in gliomas should first be the infiltration of microscopic tumour cells and the accumulation of metabolites and then the formation of tumors and corresponding tumor blood vessels (27). Notably, there are many techniques used in the preoperative evaluation of brain stromal tumors, including PWI, DWI, MRS, etc. Compared with the improved enhancement caused by the destruction of the BBB (usually HGGs are more likely to cause BBB disruption than LGGs), PWI can more effectively respond to the blood supply of gliomas, and the range of APT that can respond to substance metabolism should be larger than that of PWI (28, 29). Some of our patients also underwent PWI. For example, the suitable range for PWI in the patient with HGG in Figure 4 was also significantly smaller than that of APT. If enough similar patients are evaluated, this result should be verifiable. Compared with PWI, DWI or conventional MRI, APT may have higher sensitivity in the early stage of brain tumour infiltration, and it also has a certain role in determining the tumour infiltration boundary. Thus, it is helpful for determining the scope of surgery.

Importantly, there are two main ways to verify the imaging boundary of glioma brain infiltration: 1. Pathological examination of the area showing changes on images; if the corresponding pathological results could be obtained, they could be directly confirmed. However, the main difficulty of this method lies in the extended clinical resection and the correspondence between pathological tissue and imaging. 2. For the correspondence

FIGURE 3 | Comparison of the APT enlargement range ($R^{APT/T2}$ and $R^{APT/E}$) between meningiomas and gliomas (LGG and HGG).
between the scope of resection and preoperative images, the patients were followed up for recurrence, and the survival time was recorded. At present, many studies have proven that APT can be applied to the judgement of recurrence and pseudo-progression. However, if the lesions can be completely removed before surgery, the patients’ prognosis and treatment can be improved, and the need for a second surgery can be reduced (30).

Limitations of our research: 1. The number of patients was relatively small. 2. There was a lack of pathological results for whether the enlarged area of APT compared with conventional MR was a brain area infiltrated with tumors. 3. At present, this was only a study comparing APT and conventional MR images; if adequate functional imaging evaluation can be added, it will be possible to evaluate patients with brain tumors more comprehensively.

In conclusion, this study found that $R^{\text{APT/E}}$, $R^{\text{APT/T2}}$ and APT mean can be better for the differential diagnosis of glioma and meningioma. APT combined with conventional imaging enhancement can better differentiate between LGGs, HGGs and meningiomas.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Clinical Research Ethics Committee of Shenzhen Second People’s Hospital. Written informed consent from the participants’ legal guardian/next of kin was not required to participate in this study in accordance with the national legislation and the institutional requirements.

AUTHOR CONTRIBUTIONS

H-WZ contributed to the conception of the study; H-BZ, Y-QL, and X-LL contributed significantly to analysis and manuscript preparation; KD, FL, and Y-LW performed the data analyses and wrote the manuscript; YL, BH, and Y-NF helped perform the analysis with constructive discussions. All authors contributed to the article and approved the submitted version.

FUNDING

This study is supported by a grant from National Natural Science Foundation of China (Grant Number: 82071871), Youth Exploration Fund of Shenzhen Health Economics Society (Grant Number: 202211), Clinical Research Project of Shenzhen Second People’s Hospital, China (Grant Number: 20193357021), and Clinical Research Project of Shenzhen Second People’s Hospital, China (Grant Number: 20203357036).

ACKNOWLEDGMENTS

We would like to thank Ms. Siling Gu for her help in this research.

REFERENCES

1. Heiden MGV, Cantley LC, Thompson CB. Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation. Science (2009) 324 (5930):1029–33. doi: 10.1126/science.1160809

2. Gomes AP, Ilter D, Low V, Endress JE, Fernández-García J, Rosenzweig A, et al. Age-Induced Accumulation of Methylmalonic Acid Promotes Tumour Progression. Nature (2020) 585(7824):283. doi: 10.1038/s41586-020-2630-0

3. Ohshima K, Morii E. Metabolic Reprogramming of Cancer Cells During Tumor Progression and Metastasis. Metabolites (2021) 11(1):28. doi: 10.3390/metabo11010028

4. Venkataramani V, Tanev DI, Strahle C, Studier-Fischer A, Fankhauser L, Kessler T, et al. Glutamatergic Synaptic Input to Glioma Cells Drives Brain Tumour Progression. Nature (2019) 573(7775):532. doi: 10.1038/s41586-019-1564-x

5. Smits M, van den Bent MJ. Imaging Correlates of Adult Glioma Genotypes. Radiology (2017) 284(2):316–31. doi: 10.1148/radiol.2017151930
6. Patel SH, Poisson LM, Beat DJ, Zhou Y, Cooper L, Snuderl M, et al. T2-FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower-Grade Gliomas: A TCGA/TClA Project. *Clin Cancer Res* (2017) 23(20):6078–85. doi: 10.1158/1078-0432.CCR-17-0560

7. Kumari N, Thakur N, Cho HR, Choi SJ. Assessment of Early Therapeutic Response to Nitroxoline in Temozolomide-Resistant Glioblastoma by Amide Proton Transfer Imaging: A Preliminary Comparative Study With Diffusion-Weighted Imaging. *Sci Rep* (2019) 9(1):5585. doi: 10.1038/s41598-019-42088-y

8. Suh CH, Kim HS, Jung SC, Choi CG, Kim SJ, et al. Comparative Analysis of the MRI Characteristics of Meningiomas According to the 2016 WHO Pathological Classification. *Technol Cancer Res Treat* (2020) 19:1533033820983287. doi: 10.1177/1533033820983287

9. Yu J, Chen FF, Zhang HW, Zhang H, Luo SP, Huang GD, et al. Comparative Analysis of Amide Proton Transfer Imaging: A Preliminary Comparative Study With Diffusion-Weighted Imaging. *Eur Radiol* (2020) 30(5):2461–70. doi: 10.1007/s00330-019-06518-5

10. Sotirios B, Demetriou E, Topriceanu CC, Zakrzewska Z. The Role of APT Imaging in Gliomas Grading: A Systematic Review and Meta-Analysis. *Eur J Radiol* (2020) 133:109355. doi: 10.1016/j.ejrad.2020.109353

11. Suh CH, Park JE, Jung SC, Choi CG, Kim SJ, Kim HS., et al. Amide Proton Transfer Imaging in Brain Tumors Similarly to Proton Magnetic Resonance Spectroscopy Imaging (MRSI). *Eur Radiol* (2019) 29(3):1203–10. doi: 10.1007/s00330-018-5615-8

12. Dai H, Jiang C, Wu G, Huang R, Jin X, Zhang Z, et al. A Combined DTI and Resting State Functional MRI Study in Patients With Postherpetic Neuralgia. *Japanese J Radiol* (2020) 38(5):440–50. doi: 10.1186/s11604-020-00926-4

13. Sotirios B, Demetriou E, Topriceanu CC, Zakrzewska Z. The Role of APT Imaging in Gliomas Grading: A Systematic Review and Meta-Analysis. *Eur J Radiol* (2020) 133:109355. doi: 10.1016/j.ejrad.2020.109353

14. Suh CH, Park JE, Jung SC, Choi CG, Kim SJ, Kim HS., et al. Amide Proton Transfer Imaging: A Preliminary Comparative Study With Diffusion-Weighted Imaging. *Eur Radiol* (2019) 29(3):1203–10. doi: 10.1007/s00330-018-5615-8

15. Park JE KH, Cho HR, Choi SJ. Assessment of Early Therapeutic Response to Nitroxoline in Temozolomide-Resistant Glioblastoma by Amide Proton Transfer Imaging: A Preliminary Comparative Study With Diffusion-Weighted Imaging. *Sci Rep* (2019) 9(1):5585. doi: 10.1038/s41598-019-42088-y

16. Suh CH, Park JE, Jung SC, Choi CG, Kim SJ, et al. Comparative Analysis of Amide Proton Transfer Imaging: A Preliminary Comparative Study With Diffusion-Weighted Imaging. *Eur Radiol* (2020) 30(5):2461–70. doi: 10.1007/s00330-019-06518-5

17. Suh CH, Park JE, Jung SC, Choi CG, Kim SJ, et al. Comparative Analysis of Amide Proton Transfer Imaging: A Preliminary Comparative Study With Diffusion-Weighted Imaging. *Eur Radiol* (2020) 30(5):2461–70. doi: 10.1007/s00330-019-06518-5

18. Zhou J, Heo HY, Knutsson L, Zijl PV, Jiang S. APT-Weighted MRI: Application of 3.0 T Magnetic Resonance Chemical Exchange Saturation Transfer Imaging in Brain Metastasis of Lung Cancer. *BMJ Med Imaging* (2020) 20(1):4. doi: 10.1186/s12880-019-0400-y

19. Yu H, Lou H, Zou T, Wang X, Jiang S, Huang Z, et al. Applying Protein-Based Amide Proton Transfer MR Imaging to Distinguish Solitary Brain Metastases From Glioblastoma. *Eur Radiol* (2017) 27(11):4516–24. doi: 10.1007/s00330-017-4867-z

20. Kamimura K, Nakajo M, Yoneyama T, Fukukura Y, Hirano H, Goto Y, et al. Histogram Analysis of Amide Proton Transfer-Weighted Imaging: Comparison of Glioblastoma and Solitary Brain Metastasis in Enhancing Tumors and Peritumoral Regions. *Eur Radiol* (2019) 29(8):4133–40. doi: 10.1007/s00330-018-4714-9

21. Bhattacharjee R, Gupta RK, Das B, Dixit VK, Gupta P, Singh A. Penumbra Quantification From MR SWI-DWI Mismatch and its Comparison With MR ASL. PWI-DWI Mismatch in Patients With Acute Ischemic Stroke. *Nmr Biomed* (2021) 34(7):e4526. doi: 10.1002/nbm.4526

22. Gao XH, Li C. Nanoprobos Visualizing Gliomas by Crossing the Blood Brain Tumor Barrier. *Small* (2014) 10(3):426–40. doi: 10.1002/smll.201301673

23. Yan H, Wang L, Wang J, Weng X, Lei H, Wang X, et al. Two-Order Targeted Brain Tumor Imaging by Using an Optical/Paramagnetic Nanoprobe Across the Blood Brain Barrier. *ACS Nano* (2012) 6(1):410–20. doi: 10.1021/nn203749w

24. Zhang XY, Zhai YT, Jin ZY, Li C, Sun PZ, Wu Y. Preliminary Demonstration of In Vivo Quasi-Static-State CEST Postprocessing-Correction of Saturation Time and Relaxation Delay for Robust Quantification of Tumor MT and APT Effects. *Magn Reson Med* (2021) 86(2):943–53. doi: 10.1002/mrm.28764

25. Zhang HW, Lyu GW, He WJ, Lei Y, Lin F, Feng YN, et al. Differential Diagnosis of Central Lymphoma and High-Grade Glioma: Dynamic Contrast-Enhanced Histgram. *Acta Radiol* (2020) 61(9):1221–27. doi: 10.1034/j.1524-4585.2020.01715.x

26. Yan H, Wang L, Wang J, Weng X, Lei H, Wang X, et al. Two-Order Targeted Brain Tumor Imaging by Using an Optical/Paramagnetic Nanoprobe Across the Blood Brain Barrier. *ACS Nano* (2012) 6(1):410–20. doi: 10.1021/nn203749w

27. Zhang XY, Zhai YT, Jin ZY, Li C, Sun PZ, Wu Y. Preliminary Demonstration of In Vivo Quasi-Static-State CEST Postprocessing-Correction of Saturation Time and Relaxation Delay for Robust Quantification of Tumor MT and APT Effects. *Magn Reson Med* (2021) 86(2):943–53. doi: 10.1002/mrm.28764

28. Zhang HW, Lyu GW, He WJ, Lei Y, Lin F, Feng YN, et al. Differential Diagnosis of Central Lymphoma and High-Grade Glioma: Dynamic Contrast-Enhanced Histgram. *Acta Radiol* (2020) 61(9):1221–27. doi: 10.1034/j.1524-4585.2020.01715.x

29. Zhang HW, Lyu GW, He WJ, Lei Y, Lin F, Feng YN, et al. Differential Diagnosis of Central Lymphoma and High-Grade Glioma: Dynamic Contrast-Enhanced Histgram. *Acta Radiol* (2020) 61(9):1221–27. doi: 10.1034/j.1524-4585.2020.01715.x

30. Wong KK, Rostomily R, Wong STC. Prognostic Gene Discovery in Glioblastoma Patients Using Deep Learning. *Cancers (Basel)* (2019) 11(1):53. doi: 10.3390/cancers11010053

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Zhang, Liu, Zhang, Li, Wang, Deng, Lei, Huang and Lin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.